Attached files
| file | filename |
|---|---|
| 8-K - 8-K - LUMOS PHARMA, INC. | nlnk-20160107x8k.htm |
| EX-10.3 - EXHIBIT 10.3 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex103.htm |
| EX-10.7 - EXHIBIT 10.7 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex107.htm |
| EX-10.5 - EXHIBIT 10.5 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex105.htm |
| EX-10.1 - EXHIBIT 10.1 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex101.htm |
| EX-10.6 - EXHIBIT 10.6 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex106.htm |
| EX-10.4 - EXHIBIT 10.4 - LUMOS PHARMA, INC. | nlnk-20160107x8kxex104.htm |
Exhibit 10.2
2016 Salaries, Bonus Targets and Equity Awards | |||||||
Name and Title | 2016 Salary | Bonus Target* | Stock Options | Restricted Stock Unit Awards | Performance Restricted Stock Unit Awards# | ||
Charles J. Link, Jr., M.D. | $659,900 | 70% | 133,435 | 46,639 | 28,053 | ||
Chairman of the Board and Chief Executive and Scientific Officer | |||||||
Nicholas N. Vahanian, M.D. | $574,300 | 50% | 84,275 | 29,456 | 19,637 | ||
Director, President and Chief Medical Officer | |||||||
John B. Henneman, III | $423,600 | 40% | 46,351 | 16,201 | 9,819 | ||
Chief Financial Officer | |||||||
Carl Langren | $277,500 | 30% | 8,989 | 3,142 | 1,122 | ||
Vice President of Finance | |||||||
Brian Wiley | $370,700 | 35% | 18,259 | 6,382 | 7,013 | ||
Chief Commercial Officer | |||||||
* | Bonus Targets listed as percentage of 2016 Base Salary | ||||||
# | Performance Restricted Stock Unit Awards shall vest on the following schedule: (i) 50% of the shares underlying such RSU shall vest if the Company’s Phase 3 IMPRESS trial meets a statistically significant positive endpoint, (ii) 25% of the shares underlying such RSU shall vest if the Company’s NDA for Algenpantucel is accepted for filing by the FDA and (iii) 25% of the shares underlying such RSU shall vest if GDC-0919 advances into Phase 2 development and the Company receives a milestone payment related to such advancement pursuant to the terms of the License and Collaboration Agreement dated October 16, 2014 by and among the Company, NewLink Global, Genentech, Inc. and F. Hoffmann-LaRoche Ltd., as the same may be amended from time to time | ||||||